Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor

Jason Chesney; Jennifer Clark; Lilibeth Lanceta; John O. Trent; Sucheta Telang

doi:10.18632/oncotarget.4534

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor

Jason Chesney, Jennifer Clark, Lilibeth Lanceta, John O. Trent and Sucheta Telang _

PDF | HTML | How to cite

Oncotarget. 2015; 6:18001-18011. https://doi.org/10.18632/oncotarget.4534

Metrics: PDF 2716 views | HTML 3586 views | ?

Abstract

Jason Chesney1,2, Jennifer Clark1, Lilibeth Lanceta1, John O. Trent1,2 and Sucheta Telang1,2,3

1 Division of Hematology/Oncology, Department of Medicine, J. Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA

2 Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, USA

3 Department of Pediatrics, University of Louisville, Louisville, KY, USA

Correspondence to:

Sucheta Telang, email:

Keywords: glycolysis, 6-phosphofructo-2-kinase, fructose-2, 6-bisphosphate, tumor metabolism

Received: April 26, 2015 Accepted: June 02, 2015 Published: June 19, 2015

Abstract

Human tumors exhibit increased glucose uptake and metabolism as a result of high demand for ATP and anabolic substrates and this metabolotype is a negative prognostic indicator for survival. Recent studies have demonstrated that cancer cells from several tissue origins and genetic backgrounds require the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4), a regulatory enzyme that synthesizes an allosteric activator of glycolysis, fructose-2,6-bisphosphate. We report the discovery of a first-in-class PFKFB4 inhibitor, 5-(n-(8-methoxy-4-quinolyl)amino)pentyl nitrate (5MPN), using structure-based virtual computational screening. We find that 5MPN is a selective inhibitor of PFKFB4 that suppresses the glycolysis and proliferation of multiple human cancer cell lines but not non-transformed epithelial cells in vitro. Importantly, 5MPN has high oral bioavailability and per os administration of a non-toxic dose of 5MPN suppresses the glucose metabolism and growth of tumors in mice.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4534

Publication Alerts

Research Papers:

Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor

Abstract